Prime

Type your tag names separated by a space and hit enter

Clinical spectrum of levodopa-induced complications.

Abstract

The first years of Parkinson disease (PD) treatment are marked by good and sustained responses to dopaminergic therapy. With disease progression and longer exposure to levodopa (l-dopa), patients develop a range of l-dopa-induced complications that include motor and non-motor symptoms. Motor complications include motor fluctuations, characterized by periods of reduced benefit from the medication, and l-dopa-induced dyskinesia, characterized by emergence of hyperkinetic involuntary movements. Dyskinesia can occur at peak effect of l-dopa, at the beginning and end of dose, or between doses. These motor complications are often associated with fluctuations in non-motor symptoms, particularly fluctuations in neuropsychiatric, autonomic, and sensory symptoms. Recognizing such complications and understanding their relationship with the timing of l-dopa doses is essential for adequate diagnosis and management. Society.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Movement Disorder Centre, Edmond J Safra Program in Parkinson Research, Toronto Western Hospital, University of Toronto, Canada.

    Source

    MeSH

    Animals
    Antiparkinson Agents
    Dyskinesia, Drug-Induced
    Humans
    Levodopa
    Parkinson Disease

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    25488260

    Citation

    TY - JOUR T1 - Clinical spectrum of levodopa-induced complications. AU - Aquino,Camila Catherine, AU - Fox,Susan H, Y1 - 2014/12/08/ PY - 2014/8/20/received PY - 2014/10/20/revised PY - 2014/11/24/accepted PY - 2014/12/8/aheadofprint PY - 2014/12/10/entrez PY - 2014/12/10/pubmed PY - 2015/9/12/medline SP - 80 EP - 9 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov. Disord. VL - 30 IS - 1 N2 - The first years of Parkinson disease (PD) treatment are marked by good and sustained responses to dopaminergic therapy. With disease progression and longer exposure to levodopa (l-dopa), patients develop a range of l-dopa-induced complications that include motor and non-motor symptoms. Motor complications include motor fluctuations, characterized by periods of reduced benefit from the medication, and l-dopa-induced dyskinesia, characterized by emergence of hyperkinetic involuntary movements. Dyskinesia can occur at peak effect of l-dopa, at the beginning and end of dose, or between doses. These motor complications are often associated with fluctuations in non-motor symptoms, particularly fluctuations in neuropsychiatric, autonomic, and sensory symptoms. Recognizing such complications and understanding their relationship with the timing of l-dopa doses is essential for adequate diagnosis and management. Society. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/25488260/full_citation L2 - http://dx.doi.org/10.1002/mds.26125 ER -